The global anti-epileptic drugs market is predicted to register exponential growth rate between 2023 and 2028 owing to upsurge in government funding for developing effective and new drugs for seizure treatment. For instance, American Epilepsy Society (AES) in partnership with other organizations such as Epilepsy Foundation, Academy of Neurology, and Grass Foundation offers funding for research.
Development of awareness programs will further improve the global anti-epileptic market revenue over the forecast time frame. Various organizations conducting these awareness programs include Epilepsy Association of Central Florida, Anita Kaufmann Foundation, Epilepsy Foundation, and CURE Epilepsy.
The anti-epileptic drugs market is segmented on the lines of its product, application, end-use and regional. The basis of drug the market is segmented into First Generation AEDs Second Generation AEDs, and Third Generation AEDs. Based on distribution channel the global anti-epileptic drugs market covers Retail Pharmacies, Hospitals pharmacies, Drug-store, Mail order pharmacies, and e-commerce. The anti-epileptic drugs market on geographic segmentation covers various regions such as North America, Europe, Asia Pacific, and Rest of World. Each geographic market is further segmented to provide market revenue for selected countries such as the U.S., Canada, Germany, UK, France, Italy, China, India, Japan, Brazil, South Africa and others.
Competitive Rivalry
Pfizer Inc., Eisai Inc., GlaxoSmithKline PLC, UCB Biosciences Inc., Sanofi, Otsuka Pharmaceutical LTD., Sumitomo Dainippon Pharma Co., H. Lundbeck, and Shire PLC are among the major players in the global anti-epileptic drugs market share. The companies are involved in several growth and expansion strategies to gain a competitive advantage. Industry participants also follow value chain integration with business operations in multiple stages of the value chain.
The Anti-Epileptic Drugs Market has been segmented as below:
Anti-Epileptic Drugs Market, By Drug
Anti-Epileptic Drugs Market, By Distribution Channel
Anti-Epileptic Drugs Market, By Region
The report covers:
Report scope:
The scope of the report includes a detailed study of anti-epileptic drugs market with the reasons given for variations in the growth of the industry in certain regions.
The report covers a detailed competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled in the report include Pfizer Inc., Eisai Inc., GlaxoSmithKline PLC, UCB Biosciences Inc., Sanofi, Otsuka Pharmaceutical LTD., Sumitomo Dainippon Pharma Co., H. Lundbeck, and Shire PLC. Company profile includes assigning such as company overview, product landscape, financial overview, and recent developments.
The top company reports are intended to provide our buyers with a snapshot of the industry’s most influential players.
Reasons to Buy this Report:
Customization:
We can offer you custom research reports as per client’s special requirements
Below are our New Reports :-
1. Introduction
1.1. Key Points
1.2. Report Description
1.3. Markets Covered
1.4. Stakeholders
2. Research Methodology
2.1. Research Scope
2.2. Research Methodology
2.2.1. Market Research Process
2.2.2. Research Methodology
2.2.2.1. Secondary Research
2.2.2.2. Primary Research
2.2.2.3. Models for Estimation
2.3. Market Size Estimation
2.3.1. Bottom-Up Approach
2.3.2. Top-Down Approach
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Drivers
4.2.1. Presence of promising pipeline for epilepsy therapeutics
4.2.2. Need-gap for adequate seizure control
4.3. Restraints
4.3.1. High treatment cost
4.4. Opportunities
4.4.1. Advent of more adjunct therapies
4.5. Challenges
4.5.1. Competition from generic drugs
5. Anti-Epileptic Drugs Market, By Product
5.1. Key Points
5.2. First Generation AEDs
5.2.1. Phenytoin, Carbamazepine
5.2.2. Oxycarbazepine
5.2.3. Valproate
5.2.4. Topiramate
5.2.5. Ethosuximide
5.2.6. Primidone
5.2.7. Phenobarbital
5.3. Second Generation AEDs
5.3.1. Lamotrigine
5.3.2. Pregabalin
5.3.3. Rufinamide
5.3.4. Levetiracetam
5.3.5. Ezogabine
5.3.6. Lacosamide
5.3.7. Eslicarbazepine Acetate
5.3.8. Zonisamide
5.3.9. Perampanel
5.4. Third Generation AEDs
6. Anti-Epileptic Drugs Market, By Distribution Channel
6.1.1. Retail Pharmacies
6.1.2. Hospitals pharmacies
6.1.3. Drug-store
6.1.4. Mail order pharmacies
6.1.5. Onlinee-commerce
7. Competitive Landscape
7.1. Introduction
7.2. Recent Developments
7.2.1. Mergers & Acquisitions
7.2.2. New Product Developments
7.2.3. Portfolio/Production Capacity Expansions
7.2.4. Joint Ventures, Collaborations, Partnerships & Agreements
7.2.5. Others
8. Company Profile
8.1. Pfizer Inc.
8.1.1. Company Overview
8.1.2. Product/Service Landscape
8.1.3. Financial Overview
8.1.4. Recent Developments
8.2. Eisai Inc
8.2.1. Company Overview
8.2.2. Product/Service Landscape
8.2.3. Financial Overview
8.2.4. Recent Developments
8.3. GlaxoSmithKline PLC
8.3.1. Company Overview
8.3.2. Product/Service Landscape
8.3.3. Financial Overview
8.3.4. Recent Developments
8.4. UCB Biosciences Inc.
8.4.1. Company Overview
8.4.2. Product/Service Landscape
8.4.3. Financial Overview
8.4.4. Recent Developments
8.5. Sanofi
8.5.1. Company Overview
8.5.2. Product/Service Landscape
8.5.3. Financial Overview
8.5.4. Recent Developments
8.6. Otsuka Pharmaceutical LTD.
8.6.1. Company Overview
8.6.2. Product/Service Landscape
8.6.3. Financial Overview
8.6.4. Recent Developments
8.7. Sumitomo Dainippon Pharma Co.
8.7.1. Company Overview
8.7.2. Product/Service Landscape
8.7.3. Financial Overview
8.7.4. Recent Developments
8.8. H. Lundbeck
8.8.1. Company Overview
8.8.2. Product/Service Landscape
8.8.3. Financial Overview
8.8.4. Recent Developments
8.9. Shire PLC
8.9.1. Company Overview
8.9.2. Product/Service Landscape
8.9.3. Financial Overview
8.9.4. Recent Developments
The Anti-Epileptic Drugs Market has been segmented as below:
Anti-Epileptic Drugs Market, By Drug
Anti-Epileptic Drugs Market, By Distribution Channel
Anti-Epileptic Drugs Market, By Region
SUBSCRIBE TO OUR NEWSLETTERS
